Clinical development of an anti-GPC-1 antibody for the treatment of cancer.
Saikat GhoshPie HudaNicholas FletcherDouglas CampbellKristofer J ThurechtBradley J WalshPublished in: Expert opinion on biological therapy (2022)
Clinical development of novel anti-GPC-1 antibody-based formats is still in its early days. Using the patented anti-GPC-1 Miltuximab® as a case study, we have made an attempt to illustrate a pathway for preclinical to clinical translation, which could be useful for newer GPC-1 targeting immunotherapy agents.